# Nuclide record nct06784752 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06784752/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06784752", "NCT06784752" ;
  schema:name "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET"@en ;
  schema:alternateName "NETTER-3"@en ;
  schema:description "A phase 3 trial of [177Lu]Lu-DOTA-TATE in pancreatic ductal adenocarcinoma, run by Novartis Pharmaceuticals, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06784752/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06784752> ;
  nuclide:status "recruiting" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:companies <https://nuclide.cc/companies/advanced-accelerator-applications/> .